Roche Holding AG (RHHBY)
| Market Cap | 389.13B +34.6% |
| Revenue (ttm) | 77.92B -0.8% |
| Net Income | 15.27B +30.9% |
| EPS | 2.28 +30.6% |
| Shares Out | n/a |
| PE Ratio | 26.68 |
| Forward PE | 19.15 |
| Dividend | 0.97 (1.60%) |
| Ex-Dividend Date | Mar 13, 2026 |
| Volume | 1,525,024 |
| Open | 60.99 |
| Previous Close | 60.30 |
| Day's Range | 60.80 - 61.28 |
| 52-Week Range | 44.57 - 61.75 |
| Beta | 0.32 |
| Analysts | Buy |
| Price Target | 60.01 (-1.54%) |
| Earnings Date | Jan 28, 2027 |
About Roche Holding AG
Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and New Zealand. The company offers pharma solutions in the therapeutic areas of anaemia, blood and solid tumors, dermatology, haematology, infectious diseases, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation. It also provides in vitro tests for the diagnosis of various diseases, such as cancer, diabetes, Covid-19, hepatitis, human papillomavir... [Read more]
Financial Performance
In 2025, Roche Holding AG's revenue was 63.36 billion, an increase of 1.54% compared to the previous year's 62.40 billion. Earnings were 12.88 billion, an increase of 55.61%.
Financial numbers in CHF Financial StatementsAnalyst Summary
According to 8 analysts, the average rating for RHHBY stock is "Buy." The 12-month stock price target is $60.01, which is a decrease of -1.54% from the latest price.
News
Genentech announces FDA approval of Wilserdly in combination with everolimus
Genentech, a member of Roche (RHHBY), announced that the FDA has approved Wilserdly in combination with everolimus for the treatment of adults with estrogen receptor-positive, human epidermal growth f...
FDA Approves Genentech's WILSERDLY (Giredestrant), a Next-Generation Oral SERD, for ER-Positive, ESR1-Mutated Advanced Breast Cancer
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $RHHBY--Wilserdly (giredestrant) is now FDA-approved for ER+, ESR1-mutated advanced breast cancer, offering a new option to help delay disease progress...
FDA approves Roche's Wilserdly (giredestrant), a next-generation oral SERD, for ER-positive, ESR1-mutated advanced breast cancer
Basel, 16 November 2026 - Roche (SIX: RO, ROP; OTCQX: RHHBY) announced today that the United States (U.S.) Food and Drug Administration (FDA) has approved Wilserdly™ (giredestrant) in combination with...
US FDA approves Roche's oral treatment for advanced breast cancer
The US Food and Drug Administration approved Roche's oral treatment for certain patients with a type of advanced breast cancer, the regulator said on Monday.
Roche receives FDA De Novo authorization for cobas pro i 601 platform
Roche (RHHBY) announced that the FDA has granted De Novo authorization for the cobas pro i 601 platform with the Ionify Gabapentin assay, components of its cobas Mass Spec solution.
Roche receives FDA De Novo authorization for cobas® pro i 601 platform with Ionify® Gabapentin assay, advancing automated mass spectrometry for routine clinical laboratories
FDA De Novo authorization for the cobas® pro i 601 platform with Ionify® Gabapentin assay expands Roche's mass spectrometry menu into therapeutic drug monitoring. Designed to simplify traditionally c...
Genentech announces FDA approval of Gazyva for primary membranous nephropathy
Genentech, a member of Roche (RHHBY), announced that the FDA has approved Gazyva for the treatment of adult patients with primary membranous nephropathy at risk of disease progression, to induce…
Roche's Gazyva/Gazyvaro becomes the first FDA-approved treatment for primary membranous nephropathy
Basel, 16 November 2026 – Roche (SIX: RO, ROP; OTCQX: RHHBY) announced today that the US Food and Drug Administration (FDA) has approved Gazyva®/Gazyvaro® (obinutuzumab) for the treatment of adult pat...
Genentech's Gazyva Becomes the First FDA-Approved Treatment for Primary Membranous Nephropathy
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROP; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has approved Gazyva®...
Roche announces EMA’s CHMP recommended approval of Gazyva/Gazyvaro
Roche (RHHBY) announced that the European Medicines Agency’s, EMA, Committee for Medicinal Products for Human Use, CHMP, has recommended the approval of Gazyva/Gazyvaro as an add-on therapy for the tr...
CHMP recommends EU approval of Roche's Gazyva/Gazyvaro for systemic lupus erythematosus (SLE)
Basel, 13 November 2026 - Roche (SIX: RO, ROP; OTCQX: RHHBY) announced today that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of ...
Perficient Expands Its Innovation Center to Advance Roche Diagnostics' Molecular Laboratory Systems
CLUJ-NAPOCA, Romania--(BUSINESS WIRE)--Perficient, in collaboration with Roche Diagnostics, announced the expansion of its dedicated innovation center in Cluj-Napoca, Romania.
Genentech and Roche Present New Data Across Pharmaceuticals and Diagnostics From Its Growing Alzheimer's Disease Portfolio at CTAD 2026
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROP; OTCQX: RHHBY), announced today that it will present new data across its pharmaceuticals and diagnost...
Roche presents new data across pharmaceuticals and diagnostics from its growing Alzheimer's disease portfolio at CTAD 2026
Basel, 10 November 2026 - Roche (SIX: RO, ROP; OTCQX: RHHBY) announced today that it will present new data across its pharmaceuticals and diagnostics portfolios at the 19th Clinical Trials on Alzheime...
Roche price target raised to CHF 440 from CHF 400 at Citi
Citi raised the firm’s price target on Roche (RHHBY) to CHF 440 from CHF 400 and keeps a Buy rating on the shares.
Chai Discovery Announces Collaboration with Roche in AI-Driven Drug Discovery
SAN FRANCISCO--(BUSINESS WIRE)--Chai Discovery, the AI company building a computer-aided design suite for protein-based therapeutics, announced a collaboration with Roche.
Roche says FDA clears new cobas eplex RP3 panel
Roche (RHHBY) announced the U.S. FDA 510(k) clearance of the cobas eplex respiratory pathogen panel 3. Designed for the automated cobas eplex system, this flexible syndromic test offers up to…
Roche receives FDA 510(k) clearance for new cobas® eplex respiratory pathogen panel 3, enabling labs to customize respiratory testing for local patient needs
The new cobas ® eplex RP3 panel detects up to 19 viruses and bacteria, with newly added Bordetella pertussis and improved inclusivity of influenza A and SARS-CoV-2 strains, from a single sample to inf...
Roche downgraded to Neutral from Buy at UBS
UBS analyst Matthew Weston downgraded Roche (RHHBY) to Neutral from Buy with a price target of CHF 420, up from CHF 376. The firm cites valuation following the stock’s recent…
Roche strengthens cancer diagnostic portfolio with launch of test for differential diagnosis of mesothelioma
Basel, 28 October 2026 - Roche (SIX: RO, ROP; OTCQX: RHHBY) announced today the global launch of the VENTANA BAP1 (SP527)* test. This automated, ready-to-use immunohistochemistry (IHC) assay provides ...
Roche receives CE Mark for cobas smart e immunoanalyser
Roche (RHHBY) announced that it has received the CE Mark for its cobas smart e immunoanalyser, a compact, standalone platform engineered to deliver reliable testing with a planned menu of…
Roche receives CE Mark for cobas® smart e immunoanalyser, completing a portfolio that brings central-lab precision to healthcare settings ranging from small clinics to large hospital laboratories
Basel, 27 October 2026 - Roche (SIX: RO, ROP; OTCQX: RHHBY) announced today that it has received the CE Mark for its cobas smart e immunoanalyser, a compact, standalone platform engineered to deliver ...
Roche Targets Emerging Oncology Market With New Lung-Cancer Drug
The Swiss drugmaker expects a pill it is developing to become the new standard treatment for an advanced form of lung cancer, and the company's first shot at an emerging field within the oncology mark...
Genentech says Phase III Krascendo 1 study met primary, secondary endpoints
Genentech, a member of the Roche (RHHBY) Group, announced results from the Phase III Krascendo 1 study, which demonstrated the superior efficacy of investigational divarasib, a next-generation KRAS G1...
Roche says divarasib cut risk of death 44% in lung cancer trial
Swiss drugmaker Roche said on Sunday its experimental lung cancer drug divarasib reduced the risk of death by 44% compared with existing treatments in a phase III study.